Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lacosamide add-on to levetiracetam with withdrawal of sodium channel blocker AEDs in uncontrolled partial-onset seizures
2011-002461-37Phase 3Completed
- Sponsor
- UCB
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lacosamide in Focal Onset Epilepsy and epilepsy, sponsored by UCB. Primary endpoint: Retention at end of 21-week treatment period. Started Dec 2011; status: completed.
02
Drugs
lacosamide
03
Conditions
Focal Onset Epilepsyepilepsy
Beyond the preview
Go deeper on 2011-002461-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002461-37.